White House Set to Expand Medicaid Drug Pricing Deals Nationwide
President Trump announced Friday that all 50 states will receive most-favored-nation drug pricing for certain Medicaid drugs. The administration says it negotiated the prices with 26 pharmaceutical companies, including Pfizer, Eli Lilly, and Novo Nordisk.
- $27.6 billion in projected net savings for states over 10 years, per White House estimates.
- $36.6 billion in projected federal savings over 10 years, the White House Council of Economic Advisers says.
- $529 billion in total savings projected by the White House across all MFN deals.
- Medicaid covered roughly 74 million people; the federal government spent $668 billion on it in fiscal 2025.
Why it matters: Lower prices would most directly benefit state budgets rather than patients, who already pay only nominal co-payments under Medicaid.
- The announcement lands as healthcare costs and drug prices are central issues ahead of November midterm elections.
- Republicans reduced federal Medicaid spending by $1 trillion over a decade in the One Big Beautiful Bill Act last summer.
How 19 sources split on this story
Where they split: The core dispute is whether the claimed savings are real: the deal terms are not public, making independent verification impossible.
Center coverage, 11 sources: The center focuses on the scope of the announcement and flags expert skepticism about whether the GENEROUS model produces significant savings given Medicaid's existing discounts.
Semafor57mHealth wonks question who saves in Trump drug program
Reuters12hUS plans Medicaid most-favored-nation pricing for some drugs in all states, Semafor reports
Chicago Tribune4hTrump to announce all 50 states joining Medicaid drug pricing model
Fortune2h'No one knows what is in these deals': Trump set to announce new Medicaid drug pricing model amid affordability concerns | FortuneKSAKSAT 12 San Antonio4hTrump to announce all 50 states joining Medicaid drug pricing model
Newsweek33mDonald Trump strikes new drug price deal as Democrats eye midterm gains
The Hill8hWhite House set to tout Medicaid most favored nation drug pricing dealsTNDThe National Desk4hTrump to announce Medicaid drug-pricing plan in Oval Office remarks
USA Today2hTrump: Medicaid drug pricing deals reached for all 50 statesWYWKBN Youngstown2hTrump announces all 50 states joining Medicaid drug pricing modelWPWPXI Pittsburgh4hTrump announces all 50 states joining Medicaid drug pricing modelLeft coverage, 1 sources: The left highlights that savings figures are unverifiable because deal details are not public, and questions whether the program delivers real relief to patients.
Right coverage, 7 sources: The right frames the announcement as a concrete Trump win on drug costs, emphasizing state-level savings and the administration's deal-making with pharmaceutical companies.
Washington Examiner4hWATCH LIVE: Trump makes announcement from the White House
Just the News22hWatch Live: President Trump to announce drug pricing plan for Medicaid
Newsmax9hTrump Drug Pricing Plan to Cover All 50 States
NTD1hAll 50 States Join Medicaid Drug Pricing Program: Trump
RSBNetwork2hPresident Trump extends ‘Most Favored Nation’ drug prices to nationwide Medicaid programs
The Epoch Times22hAll 50 States Join Medicaid Drug Pricing Program: Trump
The Washington Times4hTrump to announce all 50 states joining Medicaid drug pricing modelWhat’s next: Kathy Hempstead of the Robert Wood Johnson Foundation says the White House wants Congress to codify the MFN deals.
- Hempstead warns that without public deal details, Congress has no clear basis for action.
- Questions remain about whether price cuts will persist after the current administration ends.
- What are the specific terms of the 26 pharmaceutical deals, and which drugs are covered?
- Will prices revert if a future administration does not continue the MFN program?
- How much of the projected savings reflects existing Medicaid discount mandates versus the new deals?